The QUEST trial (Chinese Clinical Trials Registry Number ChiCTR1900021929), aimed to investigate the effects of qiliqiangxin, a Traditional Chinese Medicine formulation, in patients with Heart Failure with Reduced Ejection Fraction (HFrEF). A total of 3110 HFrEF patients were randomly assigned to receive qiliqiangxin (n=1555) or a placebo (n=1555). The primary measure of efficacy was a composite event involving cardiovascular (CV) death and re-hospitalization due to deteriorating HF. After a median follow-up period of 18.3 months, the qiliqiangxin group exhibited a 25% occurrence of the primary outcome event, while the placebo group recorded a 30% incidence of the same outcome event.
Learn more about the interesting studies presented at ESC Congress 2023.